Literature DB >> 7622284

Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival.

A Obermair1, C Kurz, K Czerwenka, M Thoma, A Kaider, T Wagner, G Gitsch, P Sevelda.   

Abstract

Microvessel density (MVD) and blood and lymphatic vessel invasion (BLVI) were investigated with regard to their influence on the disease-free survival (DFS) in node-negative breast cancer patients. Paraffin embedded microsections of 230 patients with T1,2 N0 breast cancer were immunohistochemically stained for factor VIII-related antigen. Every cluster consisting of more than highlighted endothelial cells was considered a countable microvessel. MVD was counted in 4 fields of 0.25 mm2 each. All MVD values are given as value for the sum of 4 fields of 0.25 mm2 each, that is, I mm2. BLVI was considered positive, when at least one tumor cell could be identified in a stained lumen. Out of 230 patients, 49 experienced local or distant recurrence and had a mean MVD of 72.4/mm2, whereas 181 patients who lived without recurrent disease had a mean MVD of 45.3/mm2. BLVI was negative in 6.2% of the cases with and in 93.8% of the cases without recurrent disease. BLVI was positive in 59.4% of the cases without and 40.6% of the cases with recurrent disease. MVD and BLVI remained the only significant prognostic factors of DFS in the Cox-Model. Tumor size, histological grade, and hormonal-receptor status were not prognostically relevant in the Cox-model. 10-year-DFS was 93.3% in BLVI-negative/MVD < or = 40/mm2 patients, 88.1% when MVD was high or BLVI was positive and 48.9% in BLVI positive/MVD < or = 40/mm2 patients. Our present data indicate that MVD and BLVI identify a very-low risk group among node-negative breast cancer patients, who will not benefit from systemic adjuvant therapy. MVD and BLVI should be used as stratification criteria in clinical trails on node-negative breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622284     DOI: 10.1002/ijc.2910620203

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer.

Authors:  J A Beliën; S Somi; J S de Jong; P J van Diest; J P Baak
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

Review 2.  The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas.

Authors:  Laura Annaratone; Eliano Cascardi; Elena Vissio; Ivana Sarotto; Ewa Chmielik; Anna Sapino; Enrico Berrino; Caterina Marchiò
Journal:  Pathobiology       Date:  2020-04-23       Impact factor: 4.342

3.  Clinical relevance of detection of lymphovascular invasion in primary melanoma using endothelial markers D2-40 and CD34.

Authors:  Amy E Rose; Paul J Christos; Dan Lackaye; Richard L Shapiro; Russell Berman; Madhu Mazumdar; Hideko Kamino; Iman Osman; Farbod Darvishian
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

4.  Cancer stem cell and its niche in malignant progression of oral potentially malignant disorders.

Authors:  Subin Surendran; Gangotri Siddappa; Amrutha Mohan; Wesley Hicks; Vijayvel Jayaprakash; Christina Mimikos; Mohammed Mahri; Fatima Almarzouki; Kayla Morrell; Ravindra Ravi; Sindhu Govindan; C N Sushma; Nisheena Raghavan; Praveen Birur; Jeyaram Ilayaraja; Mihai Merzianu; Mary Reid; Amritha Suresh; Moni Abraham Kuriakose
Journal:  Oral Oncol       Date:  2017-11-12       Impact factor: 5.337

5.  Vascular grading of angiogenesis: prognostic significance in breast cancer.

Authors:  S Hansen; D A Grabau; F B Sørensen; M Bak; W Vach; C Rose
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

6.  Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?

Authors:  B Linderholm; B Tavelin; K Grankvist; R Henriksson
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

7.  EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome.

Authors:  Mototaka Sato; Yasutomo Nakai; Wataru Nakata; Takahiro Yoshida; Koji Hatano; Atsunari Kawashima; Kazutoshi Fujita; Motohide Uemura; Hitoshi Takayama; Norio Nonomura
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

8.  The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy.

Authors:  P Manders; L V A M Beex; V C G Tjan-Heijnen; J Geurts-Moespot; T H Van Tienoven; J A Foekens; C G J Sweep
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

Review 9.  Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer.

Authors:  Domenico Ribatti; Beatrice Nico; Simona Ruggieri; Roberto Tamma; Giovanni Simone; Anita Mangia
Journal:  Transl Oncol       Date:  2016-10       Impact factor: 4.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.